Brian Segebrecht Appointed Chief Revenue Officer of ELIAS Animal Health

Brian Segebrecht has been appointed Chief Revenue Officer of ELIAS Animal Health in light of the development of the organisation’s new cancer immunotherapy (ECI).  

Segebrecht will spearhead the marketing of the immunotherapy as well as progress business collaborations to develop ELIAS’ product portfolio.   

ELIAS Cancer Immunotherapy is set to be the only adoptive cell treatment for canine osteosarcoma, a type of bone cancer in dogs.  

The corporation is seeking a $10m in an early-stage financing round to back the expansion of manufacturing and the commercial debut of ECI®.  

The head executive at ELIAS Animal Health, Tammie Wahaus, commented, “Brian’s track record of transforming commercial strategy and building value for shareholders make him the perfect fit as we move closer to the regulatory approval of ECI® in Q4 of 2024.”  

Wahaus went on to add, “His leadership at ELIAS will be critical as we continue to pursue funding to support the commercialization of our lead product, as well as the continued expansion of our portfolio of companion animal cancer therapeutics.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.